Anavex Life Sciences
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -14,729 | -12,519 | -11,449 | -10,024 |
EBIT | -28,932 | -24,566 | -22,150 | -22,006 |
Net Income | -12,214 | -10,546 | -8,622 | -10,146 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -5,180 | -11,656 | -7,318 | -5,849 |
Cash | 138,756 | 139,386 | 143,765 | 151,024 |
Basic Shares | 84,535 | 82,464 | 82,077 | 79,787 |
Annual Financials
| Values in thousands | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -47,498 | -50,082 | -41,679 | -31,063 |
EBIT | -47,498 | -46,759 | -79,134 | -57,777 |
Net Income | -47,491 | -47,977 | -37,908 | -26,280 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -2,949 | 122,858 | 7,063 | |
Free Cash Flow | -27,785 | -24,237 | -30,383 | -21,287 |
Cash | 151,024 | 149,157 | 152,107 | 29,249 |
Basic Shares | 79,787 | 76,909 | 69,802 | 58,194 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.14 |
2024-03-31 | -$0.13 |
2023-12-31 | -$0.11 |
2023-09-30 | -$0.12 |
